160 related articles for article (PubMed ID: 38524940)
1. Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes.
Oya J; Nakagami T; Hasegawa Y; Kondo Y; Katamine A; Shimizu M; Kubota R; Suda R; Babazono T
Diabetol Int; 2024 Apr; 15(2):237-243. PubMed ID: 38524940
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials.
Komatsu M; Watada H; Kaneko S; Ross Agner BF; Nishida T; Kaku K
J Diabetes Investig; 2021 Sep; 12(9):1610-1618. PubMed ID: 33595901
[TBL] [Abstract][Full Text] [Related]
3. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
[TBL] [Abstract][Full Text] [Related]
5. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
[TBL] [Abstract][Full Text] [Related]
6. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
[TBL] [Abstract][Full Text] [Related]
7. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin.
Pei Y; Agner BR; Luo B; Dong X; Li D; Liu J; Liu L; Liu M; Lu Y; Nishida T; Xu X; Mu Y
Diabetes Obes Metab; 2021 Dec; 23(12):2687-2696. PubMed ID: 34387411
[TBL] [Abstract][Full Text] [Related]
8. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
9. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
[TBL] [Abstract][Full Text] [Related]
11. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Gough SC; Bode BW; Woo VC; Rodbard HW; Linjawi S; Zacho M; Reiter PD; Buse JB
Diabetes Obes Metab; 2015 Oct; 17(10):965-73. PubMed ID: 25980900
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
Kawaguchi Y; Miyamoto S; Hajika Y; Ashida N; Hirota T; Masumoto K; Sawa J; Hamazaki K; Kumeda Y
Adv Ther; 2022 Jun; 39(6):2688-2700. PubMed ID: 35403949
[TBL] [Abstract][Full Text] [Related]
13. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
[TBL] [Abstract][Full Text] [Related]
14. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs.
Wang W; Agner BFR; Luo B; Liu L; Liu M; Peng Y; Qu S; Stachlewska KA; Wang G; Yuan G; Zhang Q; Ning G
J Diabetes; 2022 Jun; 14(6):401-413. PubMed ID: 35762390
[TBL] [Abstract][Full Text] [Related]
15. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
Vilsbøll T; Vora J; Jarlov H; Kvist K; Blonde L
Clin Drug Investig; 2016 Apr; 36(4):293-303. PubMed ID: 26894800
[TBL] [Abstract][Full Text] [Related]
16. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
17. Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.
Jang HN; Yang YS; Lee SO; Oh TJ; Koo BK; Jung HS
Endocrinol Metab (Seoul); 2019 Dec; 34(4):382-389. PubMed ID: 31884738
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
Onishi Y; Yamada K; Zacho J; Ekelund J; Iwamoto Y
J Diabetes Investig; 2017 Mar; 8(2):210-217. PubMed ID: 27560769
[TBL] [Abstract][Full Text] [Related]
19. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
[TBL] [Abstract][Full Text] [Related]
20. Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.
Cho KY; Nakamura A; Oba-Yamamoto C; Tsuchida K; Yanagiya S; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
Diabetes Metab J; 2020 Aug; 44(4):532-541. PubMed ID: 31769240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
